Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Solifenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 8/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Solifenacin SCHEMBL29850238 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL9971260 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL1735770 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL1566459 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL13298567 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL1735698 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL1478523 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL12046704 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL1566144 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL1566240 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228575-A1 | Process for the Preparation of Solifenacin and Salts Thereof | ISOCHEM (FR) | 2014-08-14 | — | — | US | claimed |
| US-20110319621-A1 | METHOD FOR THE PREPARATION OF SOLIFENACIN AND INTERMEDIATE THEREOF | MEGAFINE PHARMA(P) LTD. (IN) | 2011-12-29 | — | — | US | claimed |
| EP-1700858-B1 | Salts of a quinuclidine derivative as muscarinic M3 receptor antagonists | ASTELLAS PHARMA INC (JP) | 2008-05-28 | — | — | EP | claimed |
| US-7176219-B2 | Salts of quinuclidine derivative | ASTELLAS PHARMA INC. (JP) | 2007-02-13 | — | — | US | claimed |
| US-20060205770-A1 | NOVEL SALTS OF QUINUCLIDINE DERIVATIVE | ASTELLAS PHARMA INC. | 2006-09-14 | — | — | US | claimed |
| EP-2406257-B1 | A NEW METHOD FOR THE PREPARATION OF SOLIFENACIN AND NEW INTERMEDIATE THEREOF | MEGAFINE PHARMA P LTD (IN) | 2019-08-07 | — | — | EP | disclosed |
| US-20140228575-A1 | Process for the Preparation of Solifenacin and Salts Thereof | ISOCHEM (FR) | 2014-08-14 | — | — | US | disclosed |
| US-20140228575-A1 | Process for the Preparation of Solifenacin and Salts Thereof | ISOCHEM (FR) | 2014-08-14 | — | — | US | disclosed |
| CN-103702997-A | Process for the preparation of solifenacin and salts thereof | ISOCHEM SA | 2014-04-02 | — | — | CN | disclosed |
| US-8283470-B2 | Method for the preparation of solifenacin and intermediate thereof | MEGAFINE PHARMA(P) LTD. (IN) | 2012-10-09 | — | — | US | disclosed |
| US-8283470-B2 | Method for the preparation of solifenacin and intermediate thereof | MEGAFINE PHARMA(P) LTD. (IN) | 2012-10-09 | — | — | US | disclosed |
| US-8283470-B2 | Method for the preparation of solifenacin and intermediate thereof | MEGAFINE PHARMA(P) LTD. (IN) | 2012-10-09 | — | — | US | disclosed |
| WO-2008011462-A2 | PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2008-01-24 | — | — | WO | disclosed |
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | ASTELLAS PHARMA INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | ASTELLAS PHARMA INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1757604-A1 | PROCESS FOR PRODUCING SOLIFENACIN OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7176219-B2 | Salts of quinuclidine derivative | ASTELLAS PHARMA INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176219-B2 | Salts of quinuclidine derivative | ASTELLAS PHARMA INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20060205770-A1 | NOVEL SALTS OF QUINUCLIDINE DERIVATIVE | ASTELLAS PHARMA INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060205770-A1 | NOVEL SALTS OF QUINUCLIDINE DERIVATIVE | ASTELLAS PHARMA INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | SUCNR1, GLS, CACNA1S | CHRM3 23/4885CHRM2 92/4885CHRM1 75/4885 |
| US-20060205770-A1 | NOVEL SALTS OF QUINUCLIDINE DERIVATIVE | QDPR, TST, SUCNR1 | CHRM3 276/4885CHRM2 894/4885CHRM1 683/4885 |
| US-20110319621-A1 | METHOD FOR THE PREPARATION OF SOLIFENACIN AND INTERMEDIATE THEREOF | CHRM3, CHRNA1, ADRA1A | CHRM3 1/4885CHRM2 26/4885CHRM1 14/4885 |
| US-20140228575-A1 | Process for the Preparation of Solifenacin and Salts Thereof | NEU3, NEU4, ADRB3 | CHRM3 9/4885CHRM2 49/4885CHRM1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.